TY - JOUR T1 - Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00648-2017 VL - 50 IS - 1 SP - 1700648 AU - Jose A. Caminero AU - Alberto Piubello AU - Anna Scardigli AU - Giovanni Battista Migliori Y1 - 2017/07/01 UR - http://erj.ersjournals.com/content/50/1/1700648.abstract N2 - Drug-resistant tuberculosis (TB) has become one of the main obstacles to controlling (and eventually eliminating) this disease [1–4]. The World Health Organization (WHO) reports that the number of patients suffering from TB with resistance to rifampicin (RR-TB) or multidrug-resistant TB (MDR-TB, resistance to at least isoniazid and rifampicin) is increasing alarmingly each year. Furthermore, the treatment success rates achieved globally are suboptimal, barely exceeding 50% [1, 2, 5]. The proportion decreases to 25% in patients with extensively drug-resistant tuberculosis (XDR-TB) (MDR-TB plus resistance to at least one fluoroquinolone (FQ) and a second-line injectable (SLI) drug) and to <20% when the drug resistance profile is beyond XDR [1, 2, 5].A potential standardised regimen to manage extensively drug-resistant tuberculosis (XDR-TB) and pre-XDR cases http://ow.ly/LucH30bUjjHThe authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions and policies of their institutions.The authors wish to thank Lia D'Ambrosio and Rosella Centis (Maugeri Care and Research Institute, Tradate, Italy) for their useful comments and the support in preparing the manuscript. ER -